Arbutus Biopharma Corp (ABUS)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Arbutus Biopharma Corp.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 1 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 4.30 $ — 53% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -28.8% failed
- More than 10% revenue growth is expected for the coming year -98.5% failed
- Share count grows by less than 3% a year 8.3% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -153.2% failed
- Gross margin at 40% or higher and without meaningful erosion 97.4% failed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA 87 m net cash passed
- Operating cash flow covers the profits of the last three years -14 m failed
- Return on capital at 15% or higher, or up versus two years ago -30.5% failed
- Insiders hold at least 10% or are net buyers 20.5% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 28.1% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 4
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1.03 | 1.03 – 1.03 | 249 | 6.1% | 1 |
| 12/31/2027 | -0.12 | -0.12 – -0.12 | 4 | – | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.05 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.07 | – | 2 | -26.60 | -796.20 | -10 | -10 |
| 2025: Q1 | -0.13 | – | 2 | 15.10 | -1,390.40 | -13 | -13 |
| 2025: Q2 | 0.01 | – | 11 | 522.20 | 23.50 | -16 | -16 |
| 2025: Q3 | -0.04 | – | 1 | -60.50 | -1,463.50 | -6 | -6 |
| 2025: Q4 | -0.02 | – | 1 | -33.20 | -357.40 | -5 | -5 |
| 2026: Q1 | 0.87 | – | 179 | 10,054.50 | 94.70 | -8 | -8 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 2 | -492 | -384 | -7.24 | -58 | 203 | 276 |
| 2017 | 11 | -111 | -84 | -1.54 | -49 | 183 | 237 |
| 2018 | 6 | -90 | -57 | -1.03 | -68 | 200 | 228 |
| 2019 | 6 | -144 | -154 | -2.69 | -71 | 73 | 106 |
| 2020 | 7 | -58 | -64 | -0.84 | -51 | 102 | 137 |
| 2021 | 11 | -74 | -76 | -0.72 | -68 | 169 | 204 |
| 2022 | 39 | -65 | -69 | -0.46 | -35 | 137 | 195 |
| 2023 | 18 | -78 | -73 | -0.44 | -86 | 106 | 144 |
| 2024 | 6 | -76 | -70 | -0.38 | -65 | 97 | 132 |
| 2025 | 14 | -27 | -34 | -0.17 | -40 | 77 | 95 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
| Employees | 19 |
|---|---|
| Headquarters | Warminster, PA |
| Address | 701 Veterans Circle, 18974 Warminster, United States |
| Phone | 267 469 0914 |
| Website | arbutusbio.com |
| IPO Date | 3. Aug 2015 |
| ISIN | CA03879J1003 |
| Stock Split | 1:5 on 11/04/2010 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Lindsay Androski J.D., M.B.A. | President, CEO & Chairman | 1977 |
| Tuan Nguyen | Chief Financial Officer | 1976 |
| Andrew J. Sung | General Counsel | – |
| R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary | 1951 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.